Mdma treatment to enhance acute emotional effects profile of lsd, psilocybin or other psychedelics

Abstract

A method of enhancing positive effects of a psychedelic, by inducing a positive psychological state in an individual with an empathogen/entactogen, administering a psychedelic to the individual, and enhancing a positive response to the psychedelic. A composition including an entactogen/empathogen and a serotonergic psychedelic in the same dosage form or administered as separate compositions within a combination treatment schedule. A method of enhancing positive effects of a psychedelic, by inducing the release of endogenous monoamines, and subsequently stimulating 5-HT2A receptors.

What is claimed is: 
     
         1 . A composition comprising an empathogen/entactogen and a psychedelic in the same dosage form. 
     
     
         2 . The composition of  claim 1 , wherein said empathogen/entactogen and said psychedelic have different release profiles. 
     
     
         3 . The composition of  claim 1 , wherein said empathogen/entactogen is chosen from the group consisting of 3,4-methylenedioxymethamphetamine (MDMA), 3,4-methylendioxyamphetamine (MDA), 3,4,-methylenedioxyethylamphetamine (MDEA), 5,6-methylenedioxy-2-aminoindane (MDAI), mephedrone, methylone, 3-MMC, homologues thereof, analogues thereof, and prodrugs thereof. 
     
     
         4 . The composition of  claim 3 , wherein said empathogen/entactogen is MDMA and is present in a dose of 20-200 mg. 
     
     
         5 . The composition of  claim 1 , wherein said psychedelic is chosen from the group consisting of psilocybin, psilocin, lysergic acid diethylamide (LSD), mescaline, dimethyltryptamine (DMT), 2,5-dimethoxy-4-iodoamphetamine (DOI), 2,5-dimethoxy-4-bromoamphetamie (DOB), phenethylamine or tryptamine psychedelics, salts thereof, analogs thereof, prodrugs thereof, and homologues thereof. 
     
     
         6 . The composition of  claim 1 , wherein said psychedelic is LSD and is present in a dose of 0.05-0.3 mg.